What is Lifesplice Pharma?
Lifesplice Pharma is a biopharmaceutical company dedicated to pioneering novel therapies by precisely directing alternative splicing. The company's core focus lies in developing groundbreaking treatments for a range of debilitating diseases, including Dravet Syndrome and Alzheimer's Disease. Their research efforts, bolstered by significant NIH grant funding, center on the creation of targeted oligonucleotide therapies designed to modulate gene expression. Lifesplice Pharma aims to serve patients suffering from complex neurological disorders and to provide the medical community with advanced treatment modalities.
How much funding has Lifesplice Pharma raised?
Lifesplice Pharma has raised a total of $67K across 1 funding round:
Debt
$67K
Debt (2021): $67K with participation from PPP
Key Investors in Lifesplice Pharma
PPP
Public-Private Partnership
What's next for Lifesplice Pharma?
With its recent influx of significant expansion capital, Lifesplice Pharma is strategically positioned for accelerated growth and the scaling of its operations. This latest funding injection is expected to fuel further research and development, potentially enabling the company to advance its drug candidates through clinical trials and towards market approval. The company's commitment to addressing unmet needs in neurological disorders suggests a future focused on expanding its therapeutic portfolio and solidifying its market presence in the specialized field of gene expression modulation.
See full Lifesplice Pharma company page
